Your browser doesn't support javascript.
loading
Nano-trapping CXCL13 reduces regulatory B cells in tumor microenvironment and inhibits tumor growth.
Shen, Limei; Li, Jingjing; Liu, Qi; Das, Manisit; Song, Wantong; Zhang, Xueqiong; Tiruthani, Karthik; Dorosheva, Oleksandra; Hu, Haiyang; Lai, Samuel K; Liu, Rihe; Huang, Leaf.
Afiliação
  • Shen L; Division of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599,USA.
  • Li J; Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599,USA.
  • Liu Q; Division of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599,USA.
  • Das M; Division of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599,USA.
  • Song W; Division of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599,USA.
  • Zhang X; Division of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599,USA.
  • Tiruthani K; Division of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599,USA.
  • Dorosheva O; Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599,USA.
  • Hu H; Division of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599,USA.
  • Lai SK; Division of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599,USA.
  • Liu R; Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599,USA; Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, NC 27599, USA. Electronic address: rliu@email.unc.edu.
  • Huang L; Division of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599,USA. Electronic address: leafh@email.unc.edu.
J Control Release ; 343: 303-313, 2022 03.
Article em En | MEDLINE | ID: mdl-35104570
ABSTRACT
Interactions between different cell types in the tumor microenvironment (TME) affect tumor growth. Tumor-associated fibroblasts produce C-X-C motif chemokine ligand 13 (CXCL13) which recruits B cells to the TME. B-cells in the TME differentiate into regulatory B cells (Bregs) (IL-10+CD1d+CD5+CD138+CD19+). We highlight these Breg cells as a new important factor in the modulation of the immunosuppressive TME in different desmoplastic murine tumor models. In addition, CXCL13 also stimulates epithelial-mesenchymal transition (EMT) of the tumor cells. The tumorigenic roles of CXCL13 led us to explore an innovative anti-cancer strategy based on delivering plasmid DNA encoding a CXCL13 trap to reduce Bregs differentiation and normalize EMT, thereby suppressing tumor growth. CXCL13 trap suppressed tumor growth in pancreatic cancer, BRAF-mutant melanoma, and triple-negative breast cancer. In this study, following treatment, the affected tumor remained dormant resulting in prolonged progression-free survival of the host.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Linfócitos B Reguladores / Neoplasias de Mama Triplo Negativas / Fibroblastos Associados a Câncer Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Control Release Assunto da revista: FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Linfócitos B Reguladores / Neoplasias de Mama Triplo Negativas / Fibroblastos Associados a Câncer Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Control Release Assunto da revista: FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos